Drug Profile
Research programme: cyclin-dependent kinase 4 inhibitors - Wyeth
Latest Information Update: 28 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Class
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Oct 2009 Wyeth has been acquired by Pfizer
- 14 May 2007 Preclinical trials in Cancer in USA (unspecified route)